Faeth Therapeutics, Inc.(FTH)

Biotechnology · Rockville, MD

$26.89-0.21 (-0.77%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T20:56:50.971Z.

Stored calculation inputs

Calculation as of: 2026-10-06T20:56:50.971Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -198,697,000
Quote market capitalization: 693,190,695
Total debt · period ending 2026-06-30: 592,000
Cash · period ending 2026-06-30: 26,903,000

FMP input reference: 2e4786eb28a8a31d15cdec8f673983fbe0ec0b626c310469f8e20e074e44c13d

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

FTH EBITDA Yield Metrics

EBITDA YIELD

N/A

FTH Competitors' EBITDA Yield

FTH

Faeth Therapeutics, Inc.

Current

Market Cap

$693.19M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

WVE

Wave Life Sciences Ltd.

vs FTH

Market Cap

$693.61M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OLMA

Olema Pharmaceuticals, Inc.

vs FTH

Market Cap

$691.79M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CTKB

Cytek Biosciences, Inc.

vs FTH

Market Cap

$694.79M

EBITDA Yield

N/A

TTM Avg

0.40%

3Y Avg

0.67%

5Y Avg

0.67%

AVR

Anteris Technologies Global Corp.

vs FTH

Market Cap

$685.49M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVBP

ArriVent BioPharma, Inc.

vs FTH

Market Cap

$702.82M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SLDB

Solid Biosciences Inc.

vs FTH

Market Cap

$681.27M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

VSTM

Verastem, Inc.

vs FTH

Market Cap

$681.02M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COLL

Collegium Pharmaceutical, Inc.

vs FTH

Market Cap

$709.65M

EBITDA Yield

35.15%

TTM Avg

23.06%

3Y Avg

19.27%

5Y Avg

16.31%

MDXG

MiMedx Group, Inc.

vs FTH

Market Cap

$673.41M

EBITDA Yield

3.79%

TTM Avg

10.03%

3Y Avg

6.88%

5Y Avg

6.20%

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Faeth Therapeutics, Inc. (FTH)	$693.19M	N/A	N/A	N/A	N/A
Wave Life Sciences Ltd. (WVE)vs ›	$693.61M	N/A	N/A	N/A	N/A
Olema Pharmaceuticals, Inc. (OLMA)vs ›	$691.79M	N/A	N/A	N/A	N/A
Cytek Biosciences, Inc. (CTKB)vs ›	$694.79M	N/A	0.40%	0.67%	0.67%
Anteris Technologies Global Corp. (AVR)vs ›	$685.49M	N/A	N/A	N/A	N/A
ArriVent BioPharma, Inc. (AVBP)vs ›	$702.82M	N/A	N/A	N/A	N/A
Solid Biosciences Inc. (SLDB)vs ›	$681.27M	N/A	N/A	N/A	N/A
Verastem, Inc. (VSTM)vs ›	$681.02M	N/A	N/A	N/A	N/A
Collegium Pharmaceutical, Inc. (COLL)vs ›	$709.65M	35.15%	23.06%	19.27%	16.31%
MiMedx Group, Inc. (MDXG)vs ›	$673.41M	3.79%	10.03%	6.88%	6.20%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

FTH EBITDA Yield Metrics

FTH Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics